3 Tesla magnetic resonance spectroscopy: Cerebral gliomas vs. metastatic brain tumors. Our experience and review of the literature

International Journal of Neuroscience

Volumn 123, Issue 8, 2013, Pages 537-543

  Caivano, R ^a   Lotumolo, A ^a   Rabasco, P ^a   Zandolino, A ^a   D'antuono, F ^a   Villonio, A ^a   Lancellotti, M I ^a   Macarini, L ^b   Cammarota, A ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Brain metastases; Gliomas; Magnetic resonance spectroscopy

Indexed keywords

LACTIC ACID; LIPID;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER GRADING; COMPARATIVE STUDY; EDEMA; GLIOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METABOLITE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSPECTIVE STUDY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ASPARTIC ACID; BRAIN NEOPLASMS; CHOLINE; CREATINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLIOMA; HUMANS; LACTIC ACID; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84880454599     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.774395     Document Type: Article

References (32)

1. Law M, Yang S, Wang H, et al. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98 (Pubitemid 37444849)
2. Hsu YY, Chang CN, Wie KJ, et al. Proton magnetic resonance spectroscopic imaging of cerebral gliomas: Correlation of metabolite ratios with histopathologic grading. Chang Gung Med J 2004;27:399-407
3. Chawla S, Wang S, Wolf RL, et al. Arterial spin-Labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683-89 (Pubitemid 47598140)
4. Rijpkema M, Schuuring J, van der Meulen Y, et al. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003;16:12-18 (Pubitemid 36284831)
5. Chawla S, Oleaga L,Wang S, et al. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging 2010;20:3-8
6. Zeng QS, Li CF, Zhang K, et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007;84:63-9 (Pubitemid 47103445)
7. Murphy PS, Viviers L, Abson C, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90:781-86 (Pubitemid 38406586)
8. Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: Differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222: 715-21 (Pubitemid 34215219)
9. Chiang IC, Kuo YT, Lu CY, et al. Distinction between highgrade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004;46:619-27 (Pubitemid 39199519)
10. McBride DQ, Miller BL, Nikas DL, et al. Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol 1995;44:137-44
11. Server A, Josefsen R, Kulle B, et al. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiologica 2010;51:316-25
12. Bertossi M, Virgintino D, Maiorano E, et al.Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol 1997;2:41-9 (Pubitemid 27099728)
13. Murphy M, Loosemore A, Clifton AG, et al. The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis. Br J Neurosurg 2002;16: 329-34 (Pubitemid 35178576)
14. Martinez-Bisbal MC, Celda B. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging 2009;53:618-30
15. PoptaniH,Gupta RK, Roy R, et al.Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593-603
16. Galanaud D, Chinot O, Metellus P, et al. Input of magnetic resonance spectroscopy in gliomas explorations. Bull Cancer 2005;92:327-31 (Pubitemid 40755342)
17. Cha S, Lupo JM, Chen MH, et al. Differentiation of glioblastomamultiforme and single brainmetastases by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 2007;28:1078-84 (Pubitemid 46984546)
18. Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004;15:279-89
19. Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography and magnetic resonance imaging defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450-9 (Pubitemid 17084816)
20. Daumas-Duport C, Monsaigneo V, Blond S, et al. Serial stereotactic biopsies and CT scan gliomas: Correlative study in 100 astrocytomas, oligo-Astrocytomas and oligodendrogliomas. J Neurooncol 1987;4:317-28 (Pubitemid 17037578)
21. Ricci R, Bacci A, Tugnoli V, et al. Metabolic findings on 3T 1H-MR spectroscopy in peritumoral brain edema. Am J Neuroradiol 2007;28:1287-91 (Pubitemid 47309660)
22. Cha S, Lupo JM, Chen MH, et al. Differentiation of glioblastomamultiforme and single brainmetastases by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 2007;28:1078-84 (Pubitemid 46984546)
23. Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004;15:279-89
24. Chawla S, Zhang Y, Wang S, et al. Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. Comput Assist Tomogr 2010;34:836-41
25. Bendini M, Marton E, Feletti A, et al. Primary and metastatic intraaxial brain tumors: Prospective comparison of multivoxel 2D chemical-shift imaging (CSI) proton MR spectroscopy, perfusion MRI, and histopathological findings in a group of 159 patients. Acta Neurochir (Wien) 2011;153:403-12
26. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: Initial experience in patients with cerebral tumors. Radiology 1989;172:541-8 (Pubitemid 19184903)
27. Weber MA, Zoubaa S, Schlieter M, et al. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006;66:1899-906 (Pubitemid 44049824)
28. Fayed N, D́avila J, Medrano J, et al. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI. Eur J Radiol 2008;67:427-33
29. Young RJ, Sills AK, Brem S, et al. Neuroimaging of metastatic brain disease. Neurosurgery 2005;57:10-23
30. Kelly PJ, Daumas-Duport C, Kispert DB, et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865-74 (Pubitemid 17085708)
31. Opstad KS, Murphy MM, Willins PR, et al. Differentiation of metastases from high-grade gliomas using short echo time 1 H spectroscopy. J Magn Reson Imaging 2004;20: 187-92 (Pubitemid 38970925)
32. Fan G, Sun B,Wu Z, et al. In vivo single-Voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004;59:77-85 (Pubitemid 38054737)